99e热国产最新地址获取,成人一a毛片免费视频,一级a爱看片免费观看,最近最新中文字幕大全免费一

 
 
 

當前位置: Language Tips> 新聞播報

H7N9 vaccine trials urged as new cases continue to emerge

中國日報網 2014-02-10 10:08

分享到

 

Get Flash Player

Download

Clinical trials should be carried out sooner for H7N9 vaccine products, but it's not necessary to conduct large-scale public immunization, experts said.

Researchers at the Shanghai Public Health Clinical Center have recently developed a genetic vaccine against H7N9 and are applying for it to undergo clinical trials.

On Jan 7, Hualan Biological Engineering Inc, in Henan province, announced on its website it had finished the preclinical study of its H7N9 vaccine products and that it is waiting for the China Food and Drug Administration to approve of its application for clinical trials of the vaccine.

But the CFDA has not yet approved clinical trials on any H7N9 vaccine products, said Shu Yuelong, director of the Chinese National Influenza Center.

"How long it takes before we get a reply depends on where we are on the waiting list and whether the documentation we filed is fully prepared," said Liu Peicheng, an official at Sinovac Biotech Ltd in Beijing.

The company announced on its website on Jan 29 that it had filed an application of clinical trials for its H7N9 vaccine products.

Liu said it's possible that if H7N9 cases were to flare, the testing process would accelerate.

In 2009, when human infections of H1N1 were frequently reported, the CFDA raised the priority of H1N1 vaccine product assessments, shortening waits for testing and streamlining their path to the market.

"It's better that clinical trials (for H7N9 vaccine products) start sooner because it takes time to complete the testing," said Shu from the influenza center.

A 53-year-old man in Jiangsu province was diagnosed with H7N9 on Saturday. The provincial health bureau said he transported two truckloads of chicken feathers from butchered chickens before he got sick.

A 75-year-old woman diagnosed with H7N9 in Nanjing on Jan 30 died on Friday despite emergency treatment, the bureau said.

However, Shu said there is no need for a large-scale immunization because the infections remain sporadic and the virus doesn't transmit effectively among humans.

He Jianfeng, chief expert at the Guangdong province Center for Disease Control and Prevention, said it is not cost-effective to carry out a large-scale immunization right now. But he emphasized that an H7N9 vaccine could help guarantee large-scale immunization when the virus is found to be able to transmit among human effectively.

He doesn't expect the virus to mutate so much as to make the technology to produce H7N9 vaccines ineffective.

"As long as it remains to be H7N9, the mutation will not require much change in the technology for us to produce a vaccine against it," he said. "We'll just need a new strain of H7N9 virus to produce the vaccine with the same technology, just like we use new strains of other kinds of flu virus to produce effective vaccines every year, because the viruses, though they are the same ones, become slightly different from year to year."

Questions:

1. What is the name of the company that has its preclinical study of the H7N9 vaccine?

2. Who is the director of the Chinese National Influenza Center?

3. Where does He Jianfeng work?

Answers:

1. Hualan Biological Engineering Inc.

2. Shu Yuelong.

3. Center for Disease Control and Prevention in Guangdong province.

(中國日報網英語點津 Helen 編輯)

H7N9 vaccine trials urged as new cases continue to emerge

About the broadcaster:

H7N9 vaccine trials urged as new cases continue to emerge

Lance Crayon is a videographer and editor with China Daily. Since living in Beijing he has worked for China Radio International (CRI) and Global Times. Before moving to China he worked in the film industry in Los Angeles as a talent agent and producer. He has a B.A. in English from the University of Texas at Arlington.

 

分享到

中國日報網英語點津版權說明:凡注明來源為“中國日報網英語點津:XXX(署名)”的原創作品,除與中國日報網簽署英語點津內容授權協議的網站外,其他任何網站或單位未經允許不得非法盜鏈、轉載和使用,違者必究。如需使用,請與010-84883561聯系;凡本網注明“來源:XXX(非英語點津)”的作品,均轉載自其它媒體,目的在于傳播更多信息,其他媒體如需轉載,請與稿件來源方聯系,如產生任何問題與本網無關;本網所發布的歌曲、電影片段,版權歸原作者所有,僅供學習與研究,如果侵權,請提供版權證明,以便盡快刪除。

中國日報網雙語新聞

掃描左側二維碼

添加Chinadaily_Mobile
你想看的我們這兒都有!

中國日報雙語手機報

點擊左側圖標查看訂閱方式

中國首份雙語手機報
學英語看資訊一個都不能少!

關注和訂閱

本文相關閱讀
人氣排行
搜熱詞
 
 
精華欄目
 

閱讀

詞匯

視聽

翻譯

口語

合作

 

關于我們 | 聯系方式 | 招聘信息

Copyright by chinadaily.com.cn. All rights reserved. None of this material may be used for any commercial or public use. Reproduction in whole or in part without permission is prohibited. 版權聲明:本網站所刊登的中國日報網英語點津內容,版權屬中國日報網所有,未經協議授權,禁止下載使用。 歡迎愿意與本網站合作的單位或個人與我們聯系。

電話:8610-84883645

傳真:8610-84883500

Email: languagetips@chinadaily.com.cn